ResearchSafe

Boswellia (AKBA) vs Pentosan (Joint Pain)

A side-by-side research comparison of Boswellia (AKBA) and Pentosan (Joint Pain) across mechanism, dosing, half-life, benefits, side effects and research status.

Comparison table

AttributeBoswellia (AKBA)Pentosan (Joint Pain)
Full nameBoswellia Serrata Extract (AKBA)Pentosan Polysulfate Sodium (Cartrophen)
CategoryPain & InflammationPain & Inflammation
StatusOTC supplementFDA Approved (interstitial cystitis) / Veterinary approved
MechanismAKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining.Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage. Stimulates hyaluronic acid production by synoviocytes. Promotes proteoglycan synthesis by chondrocytes. Reduces subchondral bone remodeling via anti-inflammatory effects.
Molecular weight512.7 Da (AKBA)~4000-6000 Da (average)
Half-life~6 hours (AKBA)~24 hours
BioavailabilityLow; improved by AKBA-standardized and phytosome forms~6% oral; ~100% subcutaneous
Typical dose100-250 mg AKBA-standardized, 1-2x daily2-3 mg/kg SC (veterinary extrapolation) or 100mg oral 3x/day
Frequency1-2x dailyWeekly SC injections (4-6 course) or daily oral
RouteOral capsuleSubcutaneous injection or oral capsule

Boswellia (AKBA) reported benefits

  • Reduces joint pain and stiffness
  • Non-NSAID (stomach-sparing) anti-inflammatory
  • Supports gut inflammation (IBD research)
  • Cartilage protection
  • Anti-inflammatory via 5-LOX inhibition

Pentosan (Joint Pain) reported benefits

  • Cartilage protection and repair
  • Reduced joint inflammation
  • Improved synovial fluid
  • Disease-modifying (not just symptomatic)
  • Reduced bone marrow edema
  • Alternative to corticosteroid injections

Related comparisons

Research and educational reference only. Not medical advice.